Robert J. AmatoHershey, Pennsylvania; Philadelphia, Pennsylvania; Houston, Texas; Seattle, Washington; Los Angeles, California; Pittsburgh, Pennsylvania; and Boston, Massachusetts
G. David RoodmanHershey, Pennsylvania; Philadelphia, Pennsylvania; Houston, Texas; Seattle, Washington; Los Angeles, California; Pittsburgh, Pennsylvania; and Boston, Massachusetts
Matthew R. SmithHershey, Pennsylvania; Philadelphia, Pennsylvania; Houston, Texas; Seattle, Washington; Los Angeles, California; Pittsburgh, Pennsylvania; and Boston, Massachusetts
Cancer and its treatment can compromise bone health, leading to fracture, pain, loss of mobility, and hypercalcemia of malignancy. Bone metastasis occurs frequently in advanced prostate and breast cancers, and bony manifestations are commonplace in multiple myeloma. Osteoporosis and osteopenia may be consequences of androgen-deprivation therapy for prostate cancer, aromatase inhibition for breast cancer, or chemotherapy-induced ovarian failure. Osteoporotic bone loss and bone metastasis ultimately share a pathophysiologic pathway that stimulates bone resorption by increasing the formation and activity of osteoclasts. Important mediators of pathologic bone metabolism include substances produced by osteoblasts, such as RANKL, the receptor activator of nuclear factor kappa B ligand, which spurs osteoclast differentiation from myeloid cells. Available therapies are targeted to various steps in cascade of bone metastasis.
MohlerJ, AmlingCL, BahnsonRR et al.. NCCN clinical practice guidelines in oncology: prostate cancer, v.2.2009. Available at: http://www.nccn.org/professionals/physician_gls/PDF/prostate.pdf. Accessed May 21, 2009.
MohlerJAmlingCLBahnsonRR. NCCN clinical practice guidelines in oncology: prostate cancer, v.2.2009. Available at: http://www.nccn.org/professionals/physician_gls/PDF/prostate.pdf. Accessed May 21, 2009.
)| false
CarlsonRW, AllredDC, AndersonBO et al.. NCCN clinical practice guidelines in oncology: breast cancer, v.1.2009. Available at: http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf. Accessed May 21, 2009.
CarlsonRWAllredDCAndersonBO. NCCN clinical practice guidelines in oncology: breast cancer, v.1.2009. Available at: http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf. Accessed May 21, 2009.
)| false
AndersonKC, AlsinaM, BensingerW et al.. NCCN clinical practice guidelines in oncology: multiple myeloma, v.2.2009. Available at: http://www.nccn.org/professionals/physician_gls/PDF/myeloma.pdf. Accessed May 21, 2009.
AndersonKCAlsinaMBensingerW. NCCN clinical practice guidelines in oncology: multiple myeloma, v.2.2009. Available at: http://www.nccn.org/professionals/physician_gls/PDF/myeloma.pdf. Accessed May 21, 2009.
)| false
KoendersPG, BeexLV, LangensR et al.. Steroid hormone receptor activity of primary human breast cancer and pattern of first metastasis. Breast Cancer Res Treat1991;18:27–32.
KoendersPGBeexLVLangensR. Steroid hormone receptor activity of primary human breast cancer and pattern of first metastasis. Breast Cancer Res Treat 1991;18:27–32.
)| false
LiptonA, TheriaultRL, HortobagyiGN et al.. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastasis: long term follow-up of two randomized, placebo-controlled trials. Cancer2000;88:1082–1090.
LiptonATheriaultRLHortobagyiGN. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastasis: long term follow-up of two randomized, placebo-controlled trials. Cancer 2000;88:1082–1090.
)| false
KrupskiTL, SmithMR, LeeWC et al.. Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy. Cancer2004;101:541–549.
KrupskiTLSmithMRLeeWC. Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy. Cancer 2004;101:541–549.
)| false
SmithMR, LeeWC, BrandmanJ et al.. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol2005;23:7897–7903.
SmithMRLeeWCBrandmanJ. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol 2005;23:7897–7903.
)| false
MalkowiczSB, ChuF, ForrestJ et al.. Prevalence of osteoporosis and osteopenia during androgen deprivation (ADT) for prostate cancer: baseline data from a large randomized controlled trial [abstract]. J Clin Oncol2007;25(18 Suppl):Abstract 5116.
MalkowiczSBChuFForrestJ. Prevalence of osteoporosis and osteopenia during androgen deprivation (ADT) for prostate cancer: baseline data from a large randomized controlled trial [abstract]. J Clin Oncol 2007;25(18 Suppl):Abstract 5116.
)| false
American Cancer Society. Cancer Facts & Figures 2008. Available at: http://www.cancer.org/downloads/STT/2008CAFFfinalsecured.pdf. Accessed March 30 2009.
American Cancer Society. Cancer Facts & Figures 2008. Available at: http://www.cancer.org/downloads/STT/2008CAFFfinalsecured.pdf. Accessed March 30 2009.
)| false
SudaT, TakahashiN, UdagawaN et al.. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev1999;20:345–357.
SudaTTakahashiNUdagawaN. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 1999;20:345–357.
)| false
DaiJ, HallCL, Escara-WilkeJ et al.. Prostate cancer induces bone metastasis though Wnt-induced morphogenetic protein-dependent and independent mechanisms. Cancer Res2008;68:5785–5794.
DaiJHallCLEscara-WilkeJ. Prostate cancer induces bone metastasis though Wnt-induced morphogenetic protein-dependent and independent mechanisms. Cancer Res 2008;68:5785–5794.
)| false
FradetV, LessardL, BéginLR et al.. Nuclear factor kappa-B nuclear localization is predictive of biochemical recurrence in patients with positive margin prostate cancer. Clin Cancer Res2004;10:8460–8464.
FradetVLessardLBéginLR. Nuclear factor kappa-B nuclear localization is predictive of biochemical recurrence in patients with positive margin prostate cancer. Clin Cancer Res 2004;10:8460–8464.
)| false
CookRJ, ColemanR, BrownJ et al.. Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer. Clin Cancer Res2006;12:3361–3367.
CookRJColemanRBrownJ. Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer. Clin Cancer Res 2006;12:3361–3367.
)| false
BrufskyA. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: A Z-FAST update. Semin Oncol2006;33(Suppl 7):S13–17.
BrufskyA. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: A Z-FAST update. Semin Oncol 2006;33(Suppl 7):S13–17.
)| false
FarhatGN, TaioliE, CauleyJA et al.. The association of bone mineral density with prostate cancer risk in the Osteoporotic Fractures in Men (MrOS) study. Cancer Epidemiol Biomarkers Prev2009;18:148–154.
FarhatGNTaioliECauleyJA. The association of bone mineral density with prostate cancer risk in the Osteoporotic Fractures in Men (MrOS) study. Cancer Epidemiol Biomarkers Prev 2009;18:148–154.
)| false
LangerCJ. Early detection, management, and evidence-based clinical guidelines for bone metastases: a 2006 update. Johns Hopkins Advanced Studies in Medicine2006;6:S1057–1062.
LangerCJ. Early detection, management, and evidence-based clinical guidelines for bone metastases: a 2006 update. Johns Hopkins Advanced Studies in Medicine 2006;6:S1057–1062.
)| false
SadikM, SuurkulaM, HöglundP et al.. Improved classifications of planar whole-body bone scans using a computer-assisted diagnosis system: a multicenter, multiple-reader, multiple-case study. J Nucl Med2009;50:368–375.
SadikMSuurkulaMHöglundP. Improved classifications of planar whole-body bone scans using a computer-assisted diagnosis system: a multicenter, multiple-reader, multiple-case study. J Nucl Med 2009;50:368–375.
)| false
TianM, ZhangH, EndoK. Whole-body FDG-PET can provide more information than Tc-99m MDP bone scintigraphy for detection of bone metastases in patients with lung cancer [abstract]. J Clin Oncol2005;23(18 Suppl):Abstract 2023.
TianMZhangHEndoK. Whole-body FDG-PET can provide more information than Tc-99m MDP bone scintigraphy for detection of bone metastases in patients with lung cancer [abstract]. J Clin Oncol 2005;23(18 Suppl):Abstract 2023.
)| false
EffertPJ, BaresR, HandtS et al.. Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorine-labeled deoxyglucose. J Urol1996;155:994–998.
EffertPJBaresRHandtS. Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorine-labeled deoxyglucose. J Urol 1996;155:994–998.
)| false
Even-SapirE, MetserU, MishaniE et al.. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med2006;47:287–297.
Even-SapirEMetserUMishaniE. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med 2006;47:287–297.
)| false
WatanabeH, MonzawaS, AdachiS et al.. Can PET/CT substitute for bone scintigraphy in assessment of bone metastases in lung cancer patients[abstract]?J Clin Oncol2006;24(18 Suppl):Abstract 7203.
WatanabeHMonzawaSAdachiS. Can PET/CT substitute for bone scintigraphy in assessment of bone metastases in lung cancer patients[abstract]?J Clin Oncol 2006;24(18 Suppl):Abstract 7203.
)| false
BeheshtiM, ValiR, WaldenbergerP et al.. The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT. Mol Imaging Biol2009; in press.
BeheshtiMValiRWaldenbergerP. The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT. Mol Imaging Biol 2009; in press.
)| false
VenkitaramanR, CookGJ, DearnaleyDP et al.. Does magnetic resonance imaging of the spine have a role in the staging of prostate cancer?Clin Oncol (R Coll Radiol)2009;21:39–42.
VenkitaramanRCookGJDearnaleyDP. Does magnetic resonance imaging of the spine have a role in the staging of prostate cancer?Clin Oncol (R Coll Radiol) 2009;21:39–42.
)| false
LecouvetFE, GeukensD, StainierA et al.. Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost-effectiveness and comparison with current detection strategies. J Clin Oncol2007;25:3281–3287.
LecouvetFEGeukensDStainierA. Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost-effectiveness and comparison with current detection strategies. J Clin Oncol 2007;25:3281–3287.
)| false
FratA, AğildereM, GençoğluA et al.. Value of whole-body turbo short tau inversion recovery magnetic resonance imaging with panoramic table for detecting bone metastases: comparison with 99MTc-methylene diphosphonate scintigraphy. J Comput Assist Tomogr2006;30:151–156.
FratAAğildereMGençoğluA. Value of whole-body turbo short tau inversion recovery magnetic resonance imaging with panoramic table for detecting bone metastases: comparison with 99MTc-methylene diphosphonate scintigraphy. J Comput Assist Tomogr 2006;30:151–156.
)| false
EngelhardK, HollenbachHP, WohlfartK et al.. Comparison of whole-body MRI with automatic moving table technique and bone scintigraphy for screening for bone metastases in patients with breast cancer. Eur Radiol2004;14:99–105.
EngelhardKHollenbachHPWohlfartK. Comparison of whole-body MRI with automatic moving table technique and bone scintigraphy for screening for bone metastases in patients with breast cancer. Eur Radiol 2004;14:99–105.
)| false
SchmidtGP, SchoenbergSO, SchmidR et al.. Screening for bone metastases: whole-body MRI using a 32-channel system versus dual-modality PET-CT. Eur Radiol2007;17:939–949.
SchmidtGPSchoenbergSOSchmidR. Screening for bone metastases: whole-body MRI using a 32-channel system versus dual-modality PET-CT. Eur Radiol 2007;17:939–949.
)| false
SkrinskasT, ClemonsM, FreedmanO et al.. Automated CT-based analysis to detect changes in the prevalence of lytic bone metastases from breast cancer. Clin Exp Metastasis2009;26:97–103.
SkrinskasTClemonsMFreedmanO. Automated CT-based analysis to detect changes in the prevalence of lytic bone metastases from breast cancer. Clin Exp Metastasis 2009;26:97–103.
)| false
NackaertsK, HarperPG, ManegoldC et al.. Management of bone metastases from lung cancer: consensus recommendations from an international panel [abstract]. J Clin Oncol2008;26(18 Suppl):Abstract 19080.
NackaertsKHarperPGManegoldC. Management of bone metastases from lung cancer: consensus recommendations from an international panel [abstract]. J Clin Oncol 2008;26(18 Suppl):Abstract 19080.
)| false
WeiB, WangJ, BourneP et al.. Bone metastasis is strongly associated with estrogen receptor-positive/progesterone receptor-negative breast carcinomas. Hum Pathol2008;39:1809–1815.
WeiBWangJBourneP. Bone metastasis is strongly associated with estrogen receptor-positive/progesterone receptor-negative breast carcinomas. Hum Pathol 2008;39:1809–1815.
)| false
ConfortiR, XiaW, BouletT et al.. Cxcr4 expression and risk of bone metastasis in patients with early breast cancer [abstract]. J Clin Oncol2007;25(18 Suppl):Abstract 10610.
ConfortiRXiaWBouletT. Cxcr4 expression and risk of bone metastasis in patients with early breast cancer [abstract]. J Clin Oncol 2007;25(18 Suppl):Abstract 10610.
)| false
BentkoverJD, ShakaEC, ThomasSK et al.. Diagnosis of bone metastases and utilization of bisphosphonates among advanced prostate cancer patients [abstract]. Presented at the 2006 ASCO Prostate Cancer Symposim; February 24–26, 2006; San Francisco, California. Abstract 165.
BentkoverJDShakaECThomasSK. Diagnosis of bone metastases and utilization of bisphosphonates among advanced prostate cancer patients [abstract]. Presented at the 2006 ASCO Prostate Cancer Symposim; February 24–26, 2006; San Francisco, California. Abstract 165.
)| false
PalRP, ThiruudaianT, KhanMA. When is a bone scan study appropriate in asymptomatic men diagnosed with prostate cancer?Asian J Androl2008;10:890–895.
PalRPThiruudaianTKhanMA. When is a bone scan study appropriate in asymptomatic men diagnosed with prostate cancer?Asian J Androl 2008;10:890–895.
)| false
ChodakGW, VogelzangNJ, CaplanRJ et al.. Independent prognostic factors in patients with metastatic (stage D2) prostate cancer. The Zoladex Study Group. JAMA1991;265:618–621.
ChodakGWVogelzangNJCaplanRJ. Independent prognostic factors in patients with metastatic (stage D2) prostate cancer. The Zoladex Study Group. JAMA 1991;265:618–621.
)| false
ErnstDS, HansonJ, VennerPM. Analysis of prognostic factors in men with metastatic prostate cancer. Uro-Oncology Group of Northern Alberta. J Urol1991;146:372–376.
ErnstDSHansonJVennerPM. Analysis of prognostic factors in men with metastatic prostate cancer. Uro-Oncology Group of Northern Alberta. J Urol 1991;146:372–376.
)| false
ClarH, LangsenlehnerU, KripplP et al.. A polymorphism in the G protein beta3-subunit gene is associated with bone metastasis risk in breast cancer patients. Breast Cancer Res Treat2008;111:449–452.
ClarHLangsenlehnerUKripplP. A polymorphism in the G protein beta3-subunit gene is associated with bone metastasis risk in breast cancer patients. Breast Cancer Res Treat 2008;111:449–452.
)| false
ClarH, RennerW, KripplP et al.. The LCT 13910 C/T polymorphism as a risk factor for osteoporosis, has no impact on metastatic bone disease in breast cancer. Breast Cancer Res Treat2008;112:363–365.
ClarHRennerWKripplP. The LCT 13910 C/T polymorphism as a risk factor for osteoporosis, has no impact on metastatic bone disease in breast cancer. Breast Cancer Res Treat 2008;112:363–365.
)| false
KumazawaT, TsuchiyaN, WangL et al.. Microsatellite polymorphism of steroid hormone synthesis gene CYP11A1 is associated with advanced prostate cancer. Int J Cancer2004;110:140–144.
KumazawaTTsuchiyaNWangL. Microsatellite polymorphism of steroid hormone synthesis gene CYP11A1 is associated with advanced prostate cancer. Int J Cancer 2004;110:140–144.
)| false
BrownJE, CookRJ, MajorP et al.. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst2005;97:59–69.
BrownJECookRJMajorP. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 2005;97:59–69.
)| false
CostaL, DemersLM, Gouveia-OliveiraA et al.. Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status. J Clin Oncol2002;20:850–856.
CostaLDemersLMGouveia-OliveiraA. Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status. J Clin Oncol 2002;20:850–856.
)| false
ColemanRE, MajorP, LiptonA et al.. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol2005;23:4925–4935.
ColemanREMajorPLiptonA. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 2005;23:4925–4935.
)| false
ChaoTY, LeeSH, ChenMM et al.. Tartrate-resistant acid phosphatase 5b (TRAP 5b) as a serum marker of bone metastasis in breast cancer patients [abstract]. Proc Am Soc Clin Oncol2002;21:Abstract 3013.
ChaoTYLeeSHChenMM. Tartrate-resistant acid phosphatase 5b (TRAP 5b) as a serum marker of bone metastasis in breast cancer patients [abstract]. Proc Am Soc Clin Oncol 2002;21:Abstract 3013.
)| false
DiLibertoA, SchmidtW, FriedrichM. Prospective trial for clinical evaluation of TRACP 5b as serum marker of bone resorption and for monitoring an oral clodronate - medication in osteolytic metastases of breast carcinoma [abstract]. J Clin Oncol2004;22(18 Suppl):Abstract 862.
DiLibertoASchmidtWFriedrichM. Prospective trial for clinical evaluation of TRACP 5b as serum marker of bone resorption and for monitoring an oral clodronate - medication in osteolytic metastases of breast carcinoma [abstract]. J Clin Oncol 2004;22(18 Suppl):Abstract 862.
)| false
OzuC, NakashimaJ, HoriguchiY et al.. Prediction of bone metastases by combination of tartrate-resistant acid phosphatase, alkaline phosphatase and prostate specific antigen in patients with prostate cancer. Int J Urol2008;15:419–422.
OzuCNakashimaJHoriguchiY. Prediction of bone metastases by combination of tartrate-resistant acid phosphatase, alkaline phosphatase and prostate specific antigen in patients with prostate cancer. Int J Urol 2008;15:419–422.
)| false
de JongIJ, KoopmansN, BreeuwsmaAJ et al.. Bone turnover markers for the early detection of bone metastases in patients with prostate cancer [abstract]. Presented at the 2006 Presented at the 2006 ASCO Prostate Cancer Symposim; February 24–26, 2006; San Francisco, California. Abstract 145.
de JongIJKoopmansNBreeuwsmaAJ. Bone turnover markers for the early detection of bone metastases in patients with prostate cancer [abstract]. Presented at the 2006 Presented at the 2006 ASCO Prostate Cancer Symposim; February 24–26, 2006; San Francisco, California. Abstract 145.
)| false
KataokaA, YuasaT, KageyamaS et al.. Diagnosis of bone metastasis in men with prostate cancer by measurement of serum ICTP in combination with alkali phosphatase and prostate-specific antigen. Clin Oncol (R Coll Radiol)2006;18:480–484.
KataokaAYuasaTKageyamaS. Diagnosis of bone metastasis in men with prostate cancer by measurement of serum ICTP in combination with alkali phosphatase and prostate-specific antigen. Clin Oncol (R Coll Radiol) 2006;18:480–484.
)| false
CostaLA, AlhoI, CasimiroS et al.. Markers of bone turnover (ICTP, NTX) and serum matrix metalloproteinase 1 (MMP1) as prognostic markers in breast cancer patients (BC) with bone metastases (BM) treated with bisphosphonates (BP) [abstract]. J Clin Oncol2008;26(18 Suppl):Abstract 1024.
CostaLAAlhoICasimiroS. Markers of bone turnover (ICTP, NTX) and serum matrix metalloproteinase 1 (MMP1) as prognostic markers in breast cancer patients (BC) with bone metastases (BM) treated with bisphosphonates (BP) [abstract]. J Clin Oncol 2008;26(18 Suppl):Abstract 1024.
)| false
HallCL, DaignaultSD, ShahRB et al.. Dickkopf-1 expression increases early in prostate cancer development and decreases during progression from primary tumor to metastasis. Prostate2008;68:1396–1404.
HallCLDaignaultSDShahRB. Dickkopf-1 expression increases early in prostate cancer development and decreases during progression from primary tumor to metastasis. Prostate 2008;68:1396–1404.
)| false
ZhangL, HouX, RaoH et al.. Predictive significance of bone sialoprotein and osteopontin for bone metastases in resectable non-small cell lung cancer: a retrospective study [abstract]. J Clin Oncol2007;25(18 Suppl):Abstract 7666.
ZhangLHouXRaoH. Predictive significance of bone sialoprotein and osteopontin for bone metastases in resectable non-small cell lung cancer: a retrospective study [abstract]. J Clin Oncol 2007;25(18 Suppl):Abstract 7666.
)| false
ScagliottiG, KalebicT, VolanteM et al.. Bone sialoprotein is predictive of bone metastases in resectable non-small cell lung cancer: a retrospective case-control study. J Clin Oncol2006;24:4818–4824.
ScagliottiGKalebicTVolanteM. Bone sialoprotein is predictive of bone metastases in resectable non-small cell lung cancer: a retrospective case-control study. J Clin Oncol 2006;24:4818–4824.
)| false
van BeekER, CohenLH, LeroyIM et al.. Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates. Bone2003;33:805–811.
van BeekERCohenLHLeroyIM. Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates. Bone 2003;33:805–811.
)| false
AlamAS, BaxCM, ShankarVS et al.. Further studies on the mode of action of calcitonin on isolated rat osteoclasts: pharmacological evidence for a second site mediating intracellular Ca2+ mobilization and cell retraction. J Endocrinol1993;136:7–15.
AlamASBaxCMShankarVS. Further studies on the mode of action of calcitonin on isolated rat osteoclasts: pharmacological evidence for a second site mediating intracellular Ca2+ mobilization and cell retraction. J Endocrinol 1993;136:7–15.
)| false
MeunierPJ, RouxC, SeemanE et al.. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med2004;350:459–468.
MeunierPJRouxCSeemanE. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004;350:459–468.
)| false
ReginsterJY, SeemanE, De VernejoulMC et al.. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab2005;90:2816–2822.
ReginsterJYSeemanEDe VernejoulMC. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005;90:2816–2822.
)| false
U.S. Food and Drug Administration. Drugs@FDA: FDA Approved Drugs. Available at: http://www.accessdata.fda.gov/Scripts/cder/DrugsatFDA/index.cfm. Accessed April 13, 2009.
U.S. Food and Drug Administration. Drugs@FDA: FDA Approved Drugs. Available at: http://www.accessdata.fda.gov/Scripts/cder/DrugsatFDA/index.cfm. Accessed April 13, 2009.
)| false
PowlesT, PatersonA, McCloskeyE et al.. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer[ISRCTN83688026]. Breast Cancer Res2006;8:R13.
PowlesTPatersonAMcCloskeyE. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer[ISRCTN83688026]. Breast Cancer Res 2006;8:R13.
)| false
WinterMC, ThorpeHC, BurkinshawR et al.. The addition of zoledronic acid to neoadjuvant chemotherapy may influence pathological response – exploratory evidence for direct anti-tumor activity in breast cancer [abstract]. Presented at the 2008 San Antonio Breast Cancer Symposium; December 10–14, 2008; San Antonio, Texas. Abstract 5101
WinterMCThorpeHCBurkinshawR. The addition of zoledronic acid to neoadjuvant chemotherapy may influence pathological response – exploratory evidence for direct anti-tumor activity in breast cancer [abstract]. Presented at the 2008 San Antonio Breast Cancer Symposium; December 10–14, 2008; San Antonio, Texas. Abstract 5101)| false
SaartoT, VehmanenL, VirkkunenP, BlomqvistC. Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta Oncol2004;43:650–656.
SaartoTVehmanenLVirkkunenPBlomqvistC. Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta Oncol 2004;43:650–656.
)| false
HiragaT, WilliamsPJ, UedaA et al.. Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model. Clin Cancer Res2004;10:4559–4567.
HiragaTWilliamsPJUedaA. Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model. Clin Cancer Res 2004;10:4559–4567.
)| false
Neville-WebbeHL, Rostami-HodjeganA, EvansCA et al.. Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells. Int J Cancer2005;113:364–371.
Neville-WebbeHLRostami-HodjeganAEvansCA. Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells. Int J Cancer 2005;113:364–371.
)| false
RackBK, JueckstockJ, GenssEM et al.. Effect of zoledronate on persisting isolated tumor cells in the bone marrow of patients without recurrence of early breast cancer [abstract]. Breast Cancer Res Treat2007;106(Suppl 1):Abstract 511.
RackBKJueckstockJGenssEM. Effect of zoledronate on persisting isolated tumor cells in the bone marrow of patients without recurrence of early breast cancer [abstract]. Breast Cancer Res Treat 2007;106(Suppl 1):Abstract 511.
)| false
CetinerS, SucakGT, KahramanSA et al.. Osteonecrosis of the jaw in patients with multiple myeloma treated with zoledronic acid. J Bone Miner Metab2009;27:435–443.
CetinerSSucakGTKahramanSA. Osteonecrosis of the jaw in patients with multiple myeloma treated with zoledronic acid. J Bone Miner Metab 2009;27:435–443.
)| false
DielIJ, WeideR, KöpplerH et al.. Risk of renal impairment after treatment with ibandronate versus zoledronic acid: a retrospective medical records review. Support Care Cancer2009;17:719–725
DielIJWeideRKöpplerH. Risk of renal impairment after treatment with ibandronate versus zoledronic acid: a retrospective medical records review. Support Care Cancer 2009;17:719–725)| false
IbrahimA, ScherN, WilliamsG et al.. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases. Clin Cancer Res2003;9:2394–2399
IbrahimAScherNWilliamsG. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases. Clin Cancer Res 2003;9:2394–2399)| false
BekkerPJ, HollowayDL, RasmussenAS et al.. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res2004;19:1059–1066
BekkerPJHollowayDLRasmussenAS. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 2004;19:1059–1066)| false
FizaziK, LiptonA, MarietteX et al.. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol2009;27:1564–1571
FizaziKLiptonAMarietteX. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 2009;27:1564–1571)| false
TuSM, KimJ, PagliaroLC et al.. Therapy tolerance in selected patients with androgen-independent prostate cancer following strontium-89 combined with chemotherapy. J Clin Oncol2005;23:7904–7910
TuSMKimJPagliaroLC. Therapy tolerance in selected patients with androgen-independent prostate cancer following strontium-89 combined with chemotherapy. J Clin Oncol 2005;23:7904–7910)| false
BasileA, GiulianoG, ScuderiV et al.. Cementoplasty in the management of painful extraspinal bone metastases: our experience. Radiol Med2008;113:1018–1028
BasileAGiulianoGScuderiV. Cementoplasty in the management of painful extraspinal bone metastases: our experience. Radiol Med 2008;113:1018–1028)| false
HusseinMA, VrionisFD, AllisonR et al.. The role of vertebral augmentation in multiple myeloma: International Myeloma Working Group Consensus Statement. Leukemia2008;22:1479–1484
HusseinMAVrionisFDAllisonR. The role of vertebral augmentation in multiple myeloma: International Myeloma Working Group Consensus Statement. Leukemia 2008;22:1479–1484)| false
SaliouG, LehmannP, ValléeJN. Controlled segmental balloon kyphoplasty: a new technique for patients with heterogeneous vertebral bone density. Spine2008;33:E216–220
SaliouGLehmannPValléeJN. Controlled segmental balloon kyphoplasty: a new technique for patients with heterogeneous vertebral bone density. Spine 2008;33:E216–220)| false
RosenLS, GordonD, KaminskiM et al.. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J2001;7:377–387
RosenLSGordonDKaminskiM. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001;7:377–387)| false
EdwardsBJ, GounderM, McKoyJM et al.. Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw. Lancet Oncol2008;9:1166–1172
EdwardsBJGounderMMcKoyJM. Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw. Lancet Oncol 2008;9:1166–1172)| false
FehmT, BeckV, BanysM et al.. Bisphosphonate-induced osteonecrosis of the jaw (ONJ): incidence and risk factors in patients with breast cancer and gynecological malignancies. Gynecol Oncol2009;112:605–609.
FehmTBeckVBanysM. Bisphosphonate-induced osteonecrosis of the jaw (ONJ): incidence and risk factors in patients with breast cancer and gynecological malignancies. Gynecol Oncol 2009;112:605–609.
)| false
GallegoL, JunqueraL. Consequence of therapy discontinuation in bisphosphonate-associated osteonecrosis of the jaws. Br J Oral Maxillofac Surg2009;47:67–68
GallegoLJunqueraL. Consequence of therapy discontinuation in bisphosphonate-associated osteonecrosis of the jaws. Br J Oral Maxillofac Surg 2009;47:67–68)| false
BodyJJ, FaconT, ColemanRE et al.. A study of the biological receptor activator of nuclear factor-kappa-B ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res2006;12:1221–1228
BodyJJFaconTColemanRE. A study of the biological receptor activator of nuclear factor-kappa-B ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 2006;12:1221–1228)| false
VijR, HorvathN, SpencerA et al.. An open-label, phase 2 trial of denosumab in the treatment of relapsed (R) or plateau-phase (PP) multiple myeloma (MM) [abstract]. Blood2007;110:Abstract 1054
VijRHorvathNSpencerA. An open-label, phase 2 trial of denosumab in the treatment of relapsed (R) or plateau-phase (PP) multiple myeloma (MM) [abstract]. Blood 2007;110:Abstract 1054)| false
YaccobyS, LingW, ZhanF et al.. Antibody-based inhibition of Dkk-1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood2007;109:2106–2111
YaccobySLingWZhanF. Antibody-based inhibition of Dkk-1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood 2007;109:2106–2111)| false
TianE, ZhanF, WalkerR et al.. The role of the Wnt/b-catenin signaling antagonist Dkk-1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med2003;349:2483–2494
TianEZhanFWalkerR. The role of the Wnt/b-catenin signaling antagonist Dkk-1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003;349:2483–2494)| false
OyajobiBO, GarrettIR, GuptaA et al.. Stimulation of new bone formation by the proteasome inhibitor, bortezomib: implications for myeloma bone disease. Br J Haematol2007;139:434–438
OyajobiBOGarrettIRGuptaA. Stimulation of new bone formation by the proteasome inhibitor, bortezomib: implications for myeloma bone disease. Br J Haematol 2007;139:434–438)| false
GarrettIR, ChenD, GutierrezG et al.. Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro. J Clin Invest2003;111:1771–1782
GarrettIRChenDGutierrezG. Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro. J Clin Invest 2003;111:1771–1782)| false
GiulianiN, MorandiF, TagliaferriS et al.. The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Blood2007;110:334–338
GiulianiNMorandiFTagliaferriS. The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Blood 2007;110:334–338)| false
AliSM, LeitzelK, ChinchilliVM et al.. Relationship of serum HER-2/neu and serum CA 15-3 in patients with metastatic breast cancer. Clin Chem2002;48:1314–1320
AliSMLeitzelKChinchilliVM. Relationship of serum HER-2/neu and serum CA 15-3 in patients with metastatic breast cancer. Clin Chem 2002;48:1314–1320)| false
AlexandreJ, BleuzenP, BonneterreJ et al.. Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patients. J Clin Oncol2000;18:562–573
AlexandreJBleuzenPBonneterreJ. Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patients. J Clin Oncol 2000;18:562–573)| false
SledgeGW, NeubergD, BernardoP et al.. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol2003;21:588–592
SledgeGWNeubergDBernardoP. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 2003;21:588–592)| false
MouridsenH, GershanovichM, SunY et al.. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol2001;19:2596–2606
MouridsenHGershanovichMSunY. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001;19:2596–2606)| false
JacobsonAF, ShapiroCL, Van den AbbeeleAD, KaplanWD. Prognostic significance of the number of bone scan abnormalities at the time of initial bone metastatic recurrence in breast carcinoma. Cancer2001;91:17–24
JacobsonAFShapiroCLVan den AbbeeleADKaplanWD. Prognostic significance of the number of bone scan abnormalities at the time of initial bone metastatic recurrence in breast carcinoma. Cancer 2001;91:17–24)| false
HillnerBE, IngleJN, ChlebowskiRT et al.. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol2003;21:4042–4057
HillnerBEIngleJNChlebowskiRT. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003;21:4042–4057)| false
TannockIF, de WitR, BerryWR et al.. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med2004;351:1502–1512
TannockIFde WitRBerryWR. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502–1512)| false
PetrylakDP, TangenCM, HussainMH et al.. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med2004;351:1513–1520
PetrylakDPTangenCMHussainMH. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513–1520)| false
KindrickAV, GrossfeldGD, StierDM et al.. Use of imaging tests for staging newly diagnosed prostate cancer: trends from CaPSURE database. J Urol1998;160:2102–2106
KindrickAVGrossfeldGDStierDM. Use of imaging tests for staging newly diagnosed prostate cancer: trends from CaPSURE database. J Urol 1998;160:2102–2106)| false
HanM, PartinAW, ZahurakM et al.. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol2003;169:517–523
HanMPartinAWZahurakM. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 2003;169:517–523)| false
Dall’eraMA, HosangN, KonetyB et al.. Sociodemographic predictors of prostate cancer risk category at diagnosis: unique patterns of significant and insignificant disease. J Urol2009;181:1622–1627
Dall’eraMAHosangNKonetyB. Sociodemographic predictors of prostate cancer risk category at diagnosis: unique patterns of significant and insignificant disease. J Urol 2009;181:1622–1627)| false
LeeN, FawaazR, OlssonCA et al.. Which patients with newly diagnosed prostate cancer need a radionuclide bone scan? An analysis based on 631 patients. Int J Radiat Oncol Biol Phys2000;48:1443–1446
LeeNFawaazROlssonCA. Which patients with newly diagnosed prostate cancer need a radionuclide bone scan? An analysis based on 631 patients. Int J Radiat Oncol Biol Phys 2000;48:1443–1446)| false
WymengaLF, BoomsmaJH, GroenierK et al.. Routine bone scans in patients with prostate cancer related to serum prostate-specific antigen and alkaline phosphatase. BJU Int2001;88:226–230
WymengaLFBoomsmaJHGroenierK. Routine bone scans in patients with prostate cancer related to serum prostate-specific antigen and alkaline phosphatase. BJU Int 2001;88:226–230)| false
YapBK, ChooR, DeboerG et al.. Are serial bone scans useful for the follow-up of clinically localized, low to intermediate grade prostate cancer managed with watchful observation alone?BJU Int2003;91:613–617
YapBKChooRDeboerG. Are serial bone scans useful for the follow-up of clinically localized, low to intermediate grade prostate cancer managed with watchful observation alone?BJU Int 2003;91:613–617)| false
GomezP, ManoharanM, KimSS, SolowayMS. Radionuclide bone scintigraphy in patients with biochemical recurrence after radical prostatectomy: when is it indicated?BJU Int2004;94:299–302
GomezPManoharanMKimSSSolowayMS. Radionuclide bone scintigraphy in patients with biochemical recurrence after radical prostatectomy: when is it indicated?BJU Int 2004;94:299–302)| false
RigaudJ, TiguertR, Le NormandL et al.. Prognostic value of bone scan in patients with metastatic prostate cancer treated initially with androgen deprivation therapy. J Urol2002;168:1423–1426
RigaudJTiguertRLe NormandL. Prognostic value of bone scan in patients with metastatic prostate cancer treated initially with androgen deprivation therapy. J Urol 2002;168:1423–1426)| false
SabbatiniP, LarsonSM, KremerA et al.. Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Oncol1999;17:948–957
SabbatiniPLarsonSMKremerA. Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Oncol 1999;17:948–957)| false
CarlinBI, AndrioleGL. The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma. Cancer2000;88(12 Suppl):2989–2994
CarlinBIAndrioleGL. The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma. Cancer 2000;88(12 Suppl):2989–2994)| false
SaadF, GleasonDM, MurrayR et al.. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst2004;96:879–882
SaadFGleasonDMMurrayR. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004;96:879–882)| false
LaraPNJr, StadlerWM, LongmateJ et al.. A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases. Clin Cancer Res2006;12:1556–1563
LaraPNJrStadlerWMLongmateJ. A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases. Clin Cancer Res 2006;12:1556–1563)| false
CarducciMA, PadleyRJ, BreulJ et al.. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol2003;21:679–689
CarducciMAPadleyRJBreulJ. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol 2003;21:679–689)| false
VogelzangNJ, NelsonJB, SchulmanCC et al.. Meta-analysis of clinical trials of atrasentan 10 mg in metastatic hormone-refractory prostate cancer [abstract]. J Clin Oncol2005;23(18 Suppl):Abstract 4563
VogelzangNJNelsonJBSchulmanCC. Meta-analysis of clinical trials of atrasentan 10 mg in metastatic hormone-refractory prostate cancer [abstract]. J Clin Oncol 2005;23(18 Suppl):Abstract 4563)| false
National Osteoporosis Foundation. Fast facts on osteoporosis, 2008. Available at: http://www.nof.org/professionals/Fast_Facts_Osteoporosis.pdf. Accessed May 21, 2009
National Osteoporosis Foundation. Fast facts on osteoporosis, 2008. Available at: http://www.nof.org/professionals/Fast_Facts_Osteoporosis.pdf. Accessed May 21, 2009)| false
NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA2001;285:785–795
NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001;285:785–795)| false
National Osteoporosis Foundation. Clinician’s guide to prevention and treatment of osteoporosis. Available at: http://www.nof.org/professionals/NOF_Clinicians_Guide.pdf. Accessed May 21, 2009
National Osteoporosis Foundation. Clinician’s guide to prevention and treatment of osteoporosis. Available at: http://www.nof.org/professionals/NOF_Clinicians_Guide.pdf. Accessed May 21, 2009)| false
HershmanD, NarayananR. Prevention and management of osteoporosis in women with breast cancer and men with prostate cancer. Curr Oncol Rep2004;6:277–284
HershmanDNarayananR. Prevention and management of osteoporosis in women with breast cancer and men with prostate cancer. Curr Oncol Rep 2004;6:277–284)| false
HowellA, CuzickJ, BaumM et al.. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet2005;365:60–62
HowellACuzickJBaumM. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 2005;365:60–62)| false
BaumM, BuzdarAU, CuzickJ et al.. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet2002;359:2131–2139
BaumMBuzdarAUCuzickJ. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002;359:2131–2139)| false
GossPE, IngleJN, MartinoS et al.. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst2005;97:1262–1271
GossPEIngleJNMartinoS. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005;97:1262–1271)| false
PerezEA, JosseRG, PritchardKI et al.. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol2006;24:3629–3635
PerezEAJosseRGPritchardKI. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol 2006;24:3629–3635)| false
ThürlimannB, KeshaviahA, CoatesAS et al.. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med2005;353:2747–2757
ThürlimannBKeshaviahACoatesAS. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353:2747–2757)| false
JakeszR, JonatW, GnantM et al.. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet2005;366:455–462
JakeszRJonatWGnantM. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005;366:455–462)| false
AaproM, AbrahamssonPA, BodyJJ et al.. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol2008;19:420–432
AaproMAbrahamssonPABodyJJ. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 2008;19:420–432)| false
BrufskyA, DongM, LundK et al.. Twenty-four month follow-up of the effect of zoledronic acid on aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Presented at the 2006 San Antonio Breast Cancer Symposium; December 14–17, 2006; San Antonio, Texas. Abstract 5060
BrufskyADongMLundK. Twenty-four month follow-up of the effect of zoledronic acid on aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Presented at the 2006 San Antonio Breast Cancer Symposium; December 14–17, 2006; San Antonio, Texas. Abstract 5060)| false
BrufskyA, HarkerWG, BeckJT et al.. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol2007;25:829–836
BrufskyAHarkerWGBeckJT. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 2007;25:829–836)| false
GnantMF, MlineritschB, Luschin-EbengreuthG et al.. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol2007;25:820–828
GnantMFMlineritschBLuschin-EbengreuthG. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 2007;25:820–828)| false
Van PoznakC, HannonRA, ClackG et al.. The SABRE (Study of Anastrozole with the Bisphosphonate Risedronate) study: 12-month analysis. Presented at the 2007 San Antonio Breast Cancer Symposium; December 13–16, 2007; San Antonio, Texas. Abstract 502
Van PoznakCHannonRAClackG. The SABRE (Study of Anastrozole with the Bisphosphonate Risedronate) study: 12-month analysis. Presented at the 2007 San Antonio Breast Cancer Symposium; December 13–16, 2007; San Antonio, Texas. Abstract 502)| false
EllisGK, BoneHG, ChlebowskiR et al.. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol2008;26:4875–4882
EllisGKBoneHGChlebowskiR. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 2008;26:4875–4882)| false
MittanD, LeeS, MillerE et al.. Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab2002;87:3656–3661
MittanDLeeSMillerE. Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab 2002;87:3656–3661)| false
SpryNA, GalvãoDA, DaviesR et al.. Long-term effects of intermittent androgen suppression on testosterone recovery and bone mineral density: results of a 33-month observational study. BJU Int2009;104:806–812
SpryNAGalvãoDADaviesR. Long-term effects of intermittent androgen suppression on testosterone recovery and bone mineral density: results of a 33-month observational study. BJU Int 2009;104:806–812)| false
SmithMR, McGovernFJ, ZietmanAL et al.. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med2001;345:948–955
SmithMRMcGovernFJZietmanAL. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001;345:948–955)| false
SmithMR, EasthamJ, GleasonDM et al.. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol2003;169:2008–2012.
SmithMREasthamJGleasonDM. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003;169:2008–2012.
)| false
MichaelsonMD, KaufmanDS, KantoffP et al.. Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer. Cancer2006;107:530–535
MichaelsonMDKaufmanDSKantoffP. Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer. Cancer 2006;107:530–535)| false
GreenspanSL, NelsonJB, TrumpDL, ResnickNM. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med2007;146:416–424
GreenspanSLNelsonJBTrumpDLResnickNM. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med 2007;146:416–424)| false
KhoslaS, MeltonLJIII, AtkinsonEJ, O’FallonWM. Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. J Clin Endocrinol Metab2001;86:3555–3561
KhoslaSMeltonLJIIIAtkinsonEJO’FallonWM. Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. J Clin Endocrinol Metab 2001;86:3555–3561)| false
SmithMR, FallonMA, LeeH, FinkelsteinJS. Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab2004;89:3841–3846
SmithMRFallonMALeeHFinkelsteinJS. Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab 2004;89:3841–3846)| false
SmithMR, MalkowiczSB, ChuF et al.. Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study. J Urol2008;179:152–155
SmithMRMalkowiczSBChuF. Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study. J Urol 2008;179:152–155)| false
SmithM, MortonR, WallaceH et al.. A phase III randomized controlled trial of toremifene to prevent fractures and other adverse effects of androgen therapy in men with prostate cancer [abstract]. Presented at the 2008 American Association for Cancer Research Meeting; April 12–16, 2008; San Diego, California. Abstract LB-241
SmithMMortonRWallaceH. A phase III randomized controlled trial of toremifene to prevent fractures and other adverse effects of androgen therapy in men with prostate cancer [abstract]. Presented at the 2008 American Association for Cancer Research Meeting; April 12–16, 2008; San Diego, California. Abstract LB-241)| false
SmithMR, EgerdieB, Hernández TorizN et al.. A randomized, double-blind, placebo-controlled trial of denosumab in men receiving androgen deprivation therapy for non-metastatic prostate cancer. Presented at the 2009 European Association of Urology Meeting; March 17–21, 2009; Stockholm, Sweden.
SmithMREgerdieBHernández TorizN. A randomized, double-blind, placebo-controlled trial of denosumab in men receiving androgen deprivation therapy for non-metastatic prostate cancer. Presented at the 2009 European Association of Urology Meeting; March 17–21, 2009; Stockholm, Sweden.
)| false
